7 Best Anti-COVID Nasal Sprays (2022)
Do nasal sprays actually work against COVID-19? There has been quite a lot
of activities in the COVID nasal spray space. Below, we look at some of the
best nasal sprays for COVID-19 and summaries of the rationale and evidence
for each category. Do note that some of them are available as an
over-the-counter medication but some are still under clinical trial stage.
Best Nasal Sprays for COVID-19 (2022)
There are lots of great nasal sprays out there, and this list is by no
means complete. We’ve included nasal sprays with proven anti-COVID-19
ingredient, you can buy over the counter or online.
1. Povidone Iodine Nasal Spray and COVID-19
Povidone iodine (PVP-I) is an antiseptic that has been used for over 150 years. The antiseptic has immediate virucidal effects against COVID-19 virus. Do we have any evidence that povidone iodine is effective against COVID-19?
There are more than 15 published studies supporting povidone-iodine for COVID-19. You can check out the list below (c19pvpi.com).
.png)
Povidone-iodine is ranked no. 4 in this COVID-19 early treatment mortality results league table below. However, this is based on only 1 study.
.png)
On December 4th, 2021 interview with Rebel News, Peter McCullough MD discusses what is known about the Omicron variant, and the use of Povidone Iodine Mouthwash, Povidone Iodine Nasal Antiseptic Wash and Gargle for prevention of Covid-19. Dr. McCullough cites the Choudhury study in which 606 COVID infected patients were randomized to 1% povidone iodine, or saline placebo mouthwash and gargle. Patients were followed with PCR testing for viral load.
Dr. Iqbal Mahmud Choudhury conducted a protocol in Bangladesh that used a povidone-iodine rinse in the nose, mouth, and eyes to kill the virus. Dr. Choudhury wrote:
The group of patients used 1% PVP-I [One per cent Povidone Iodine Solution] have shown tremendously reduced mortality, morbidity and hospital as well as financial burden in this covid situation.
Povidone iodine nasal spray where to buy: Find iodine nasal spray on Amazon.
There are more than 15 published studies supporting povidone-iodine for COVID-19. You can check out the list below (c19pvpi.com).
.png)
Povidone-iodine is ranked no. 4 in this COVID-19 early treatment mortality results league table below. However, this is based on only 1 study.
.png)
On December 4th, 2021 interview with Rebel News, Peter McCullough MD discusses what is known about the Omicron variant, and the use of Povidone Iodine Mouthwash, Povidone Iodine Nasal Antiseptic Wash and Gargle for prevention of Covid-19. Dr. McCullough cites the Choudhury study in which 606 COVID infected patients were randomized to 1% povidone iodine, or saline placebo mouthwash and gargle. Patients were followed with PCR testing for viral load.
The group of patients used 1% PVP-I [One per cent Povidone Iodine Solution] have shown tremendously reduced mortality, morbidity and hospital as well as financial burden in this covid situation.
2. Saline Nasal Spray and Irrigation
A study, published in the Ear, Nose & Throat journal in August 2022, showed that rinsing your nasal passages with a saline solution within 24 hours of a COVID-19 diagnosis could reduce your chances of being hospitalized by 8.5-fold. According to the researchers:
"Our results support that pressurized nasal irrigation reduces the likelihood of hospitalization in high-risk COVID-19 + outpatients, suggesting a safe and over the counter measure with potentially vital public health impact."
Another study proposing a simple prevention/treatment method that can be made/applied in just about any country, regardless of how poor and remote it is. Namely, a simple solution of salt in water, such that the concentration of salt is about 1.5% (e.g. commonly known as “hypertonic”) in the solution, had a 100% effectiveness of stopping SARS-CoV-2 replication.
This effectiveness actually exceeds the results (90% inhibition) demonstrated by the study on low-dose vitamin E mentioned above. As the study says, this simple hypertonic saline solution can be administered as a nasal spray as a prophylactic method, or for treating early stages of the infection. For already established or more severe cases affecting the lungs, a nebulizer may have to be used so that the salt vapors can reach the lower regions of the respiratory tract.
The mechanism of action for the anti-viral effects of the saline is remarkably simple – i.e. the extra salt from the solution accumulates into the cells, which forces them to expend ATP in order to re-balance the electrolyte gradient, and this limits the amount of ATP available for viral replication. Since virtually all viruses, including SARS-CoV-2, depend for their survival on being able to hijack ATP for their own replication this study suggests hypertonic saline may be a universally applicable antiviral treatment.
Nozin Nasal Sanitizer - Available on Amazon
A study, published in the Ear, Nose & Throat journal in August 2022, showed that rinsing your nasal passages with a saline solution within 24 hours of a COVID-19 diagnosis could reduce your chances of being hospitalized by 8.5-fold. According to the researchers:
"Our results support that pressurized nasal irrigation reduces the likelihood of hospitalization in high-risk COVID-19 + outpatients, suggesting a safe and over the counter measure with potentially vital public health impact."
Another study proposing a simple prevention/treatment method that can be made/applied in just about any country, regardless of how poor and remote it is. Namely, a simple solution of salt in water, such that the concentration of salt is about 1.5% (e.g. commonly known as “hypertonic”) in the solution, had a 100% effectiveness of stopping SARS-CoV-2 replication.
This effectiveness actually exceeds the results (90% inhibition) demonstrated by the study on low-dose vitamin E mentioned above. As the study says, this simple hypertonic saline solution can be administered as a nasal spray as a prophylactic method, or for treating early stages of the infection. For already established or more severe cases affecting the lungs, a nebulizer may have to be used so that the salt vapors can reach the lower regions of the respiratory tract.
The mechanism of action for the anti-viral effects of the saline is remarkably simple – i.e. the extra salt from the solution accumulates into the cells, which forces them to expend ATP in order to re-balance the electrolyte gradient, and this limits the amount of ATP available for viral replication. Since virtually all viruses, including SARS-CoV-2, depend for their survival on being able to hijack ATP for their own replication this study suggests hypertonic saline may be a universally applicable antiviral treatment.
|
| Nozin Nasal Sanitizer - Available on Amazon |
3. Xlear Natural Saline Nasal Spray with Xylitol (Available on Amazon)
A preprint lab report suggests an Xlear nasal spray is effective at significantly reducing and nearly eliminating SARS-CoV-2, the virus that causes COVID-19 after a single dose.
An in vitro study conducted by scientists from Northwestern University and Utah State University concluded that components found within the Xlear nasal spray, particularly grapefruit seed extract and xylitol, were successful in statistically reducing the amount of SARS-CoV-2.
After a single blast, the researchers saw the nasal spray reduced virus from 4.2 to 1.7 log10 CCID50 per 0.1 mL, a statistically significant reduction of 2.5 log10 CCID50. News of the study was announced by Xlear and the company said this is only the latest research that reaches a conclusion the over-the-counter spray is effective against the virus that causes COVID-19.
Limited case reports also hint that xylitol nasal sprays may help improve COVID-19 symptoms when used with other treatments. Clinical trials are needed to confirm these findings.
Xlear is currently sold as a nasal irrigant for cleansing and moisturizing the nasal cavities.
Professor Mark Cannon of the Feinberg School of Medicine at Northwestern University said the study breaks ground in two areas.
Cannon said using electron microscopy, the researchers saw visual evidence that showed the combination of xylitol and grapefruit seed extract counters the virus. The grapefruit seed extract kills the virus, while the xylitol prevents the virus from attaching to the cell walls, Cannon said in the announcement. The study postulates that xylitol acts as a decoy target for SARS-CoV-2, preventing virus attachment to the core protein on the cell wall, he said.
“In addition to countering SARS-CoV-2, Xlear is likely effective in preventing the spread of future H1N1 viruses, including the emerging SARS-CoV-2 variants, along with other viral epidemics. Given the more transmissible variants we now face, this is critical now,” Cannon said in a statement.
That in vitro evidence will no doubt be used to support a new petition before the World Health Organization. This week, a coalition of health professionals petitioned the World Health Organization to issue Guidance calling on: “all people to use nasal sprays to combat the COVID-19 pandemic.” The petition, which is supported by Xlear, is touting data that shows these nasal sprays are able to block viral adhesion and even kill or deactivate the virus in the nasal passages. The petition calls specifically for WHO Guidance to focus on the use of nasal sprays that contain Xylitol and grapefruit seed extract, which is found in Xlear.
“Nasal sprays are proven safe, inexpensive, non-invasive, easy to use and you can get them off-the-shelf at your local store around the world. There is a growing body of data that sprays, in particular Xlear, can help combat the COVID-19 pandemic. It’s pure commonsense,” Nathan Jones, chief executive officer of Xlear said in a statement.
In March 2021, Xlear filed a Pre-Emergency Use Authorization request with the U.S. Food and Drug Administration in hopes of securing authorization of the spray as a new hygiene tool to help in combat the SARS-CoV-2 virus.
Xlear isn’t the only nasal spray that is showing promise in providing another level of protection against COVID-19, which has infected nearly 100 million people across the globe and led to the deaths more than 2 million people. Researchers from the University of Birmingham in the U.K. developed a nasal spray that can potentially provide protection against COVID-19. The spray uses compounds that are already approved by regulatory authorities in the UK, Europe and the U.S., including carrageenan, along with a gellan polysaccharide.
Another nasal spray that uses a lipopeptide, a cholesterol particle linked to a chain of amino acids, has also shown promise in preclinical testing. As BioSpace previously reported, the lipopeptide matches the stretch of amino acids in the spike protein of SARS-CoV-2 exactly. The lipopeptide attaches itself onto one of the spike’s amino acid chains and prevents viral attachment.
Where to Buy: Find Xlear on Amazon.
A preprint lab report suggests an Xlear nasal spray is effective at significantly reducing and nearly eliminating SARS-CoV-2, the virus that causes COVID-19 after a single dose.
An in vitro study conducted by scientists from Northwestern University and Utah State University concluded that components found within the Xlear nasal spray, particularly grapefruit seed extract and xylitol, were successful in statistically reducing the amount of SARS-CoV-2.
After a single blast, the researchers saw the nasal spray reduced virus from 4.2 to 1.7 log10 CCID50 per 0.1 mL, a statistically significant reduction of 2.5 log10 CCID50. News of the study was announced by Xlear and the company said this is only the latest research that reaches a conclusion the over-the-counter spray is effective against the virus that causes COVID-19.
Limited case reports also hint that xylitol nasal sprays may help improve COVID-19 symptoms when used with other treatments. Clinical trials are needed to confirm these findings.
Xlear is currently sold as a nasal irrigant for cleansing and moisturizing the nasal cavities.
Xlear is currently sold as a nasal irrigant for cleansing and moisturizing the nasal cavities.
Professor Mark Cannon of the Feinberg School of Medicine at Northwestern University said the study breaks ground in two areas.
Cannon said using electron microscopy, the researchers saw visual evidence that showed the combination of xylitol and grapefruit seed extract counters the virus. The grapefruit seed extract kills the virus, while the xylitol prevents the virus from attaching to the cell walls, Cannon said in the announcement. The study postulates that xylitol acts as a decoy target for SARS-CoV-2, preventing virus attachment to the core protein on the cell wall, he said.
“In addition to countering SARS-CoV-2, Xlear is likely effective in preventing the spread of future H1N1 viruses, including the emerging SARS-CoV-2 variants, along with other viral epidemics. Given the more transmissible variants we now face, this is critical now,” Cannon said in a statement.
That in vitro evidence will no doubt be used to support a new petition before the World Health Organization. This week, a coalition of health professionals petitioned the World Health Organization to issue Guidance calling on: “all people to use nasal sprays to combat the COVID-19 pandemic.” The petition, which is supported by Xlear, is touting data that shows these nasal sprays are able to block viral adhesion and even kill or deactivate the virus in the nasal passages. The petition calls specifically for WHO Guidance to focus on the use of nasal sprays that contain Xylitol and grapefruit seed extract, which is found in Xlear.
“Nasal sprays are proven safe, inexpensive, non-invasive, easy to use and you can get them off-the-shelf at your local store around the world. There is a growing body of data that sprays, in particular Xlear, can help combat the COVID-19 pandemic. It’s pure commonsense,” Nathan Jones, chief executive officer of Xlear said in a statement.
In March 2021, Xlear filed a Pre-Emergency Use Authorization request with the U.S. Food and Drug Administration in hopes of securing authorization of the spray as a new hygiene tool to help in combat the SARS-CoV-2 virus.
“In addition to countering SARS-CoV-2, Xlear is likely effective in preventing the spread of future H1N1 viruses, including the emerging SARS-CoV-2 variants, along with other viral epidemics. Given the more transmissible variants we now face, this is critical now,” Cannon said in a statement.
That in vitro evidence will no doubt be used to support a new petition before the World Health Organization. This week, a coalition of health professionals petitioned the World Health Organization to issue Guidance calling on: “all people to use nasal sprays to combat the COVID-19 pandemic.” The petition, which is supported by Xlear, is touting data that shows these nasal sprays are able to block viral adhesion and even kill or deactivate the virus in the nasal passages. The petition calls specifically for WHO Guidance to focus on the use of nasal sprays that contain Xylitol and grapefruit seed extract, which is found in Xlear.
“Nasal sprays are proven safe, inexpensive, non-invasive, easy to use and you can get them off-the-shelf at your local store around the world. There is a growing body of data that sprays, in particular Xlear, can help combat the COVID-19 pandemic. It’s pure commonsense,” Nathan Jones, chief executive officer of Xlear said in a statement.
In March 2021, Xlear filed a Pre-Emergency Use Authorization request with the U.S. Food and Drug Administration in hopes of securing authorization of the spray as a new hygiene tool to help in combat the SARS-CoV-2 virus.
Xlear isn’t the only nasal spray that is showing promise in providing another level of protection against COVID-19, which has infected nearly 100 million people across the globe and led to the deaths more than 2 million people. Researchers from the University of Birmingham in the U.K. developed a nasal spray that can potentially provide protection against COVID-19. The spray uses compounds that are already approved by regulatory authorities in the UK, Europe and the U.S., including carrageenan, along with a gellan polysaccharide.
Another nasal spray that uses a lipopeptide, a cholesterol particle linked to a chain of amino acids, has also shown promise in preclinical testing. As BioSpace previously reported, the lipopeptide matches the stretch of amino acids in the spike protein of SARS-CoV-2 exactly. The lipopeptide attaches itself onto one of the spike’s amino acid chains and prevents viral attachment.
Where to Buy: Find Xlear on Amazon.
4. Nitric Oxide Nasal Spray (NONS)
Nitric oxide is a type of gas that’s found all throughout your body. It has many jobs, but one of its key roles is helping regulate your immune system. Because of this, researchers are curious if nitric oxide nasal sprays could help treat mild cases of COVID-19.
In particular, a few studies have looked to see if nitric oxide nasal sprays can help prevent severe illness from developing. One small study found that it can reduce viral load by about 95% after 24 hours. And large clinical trials for nitric oxide nasal sprays are still taking place.
So far, this type of research has been influential in some countries. For instance, one nitric oxide nasal spray — called Enovid — is already available in Israel and on Amazon.com.
The product is authorized as a medical device targeting COVID-19 in India, Israel, Bahrain, Indonesia and Thailand.
Canadian biotech SaNOtize’s nitric oxide nasal spray Enovid became available in pharmacies in Israel in July 2021 as a treatment for Covid-19.
The spray received emergency use authorisation in Israel in early July 2021 after Phase II trials showed it reduces SARS-CoV-2 viral load, and therefore decrease a person’s transmission of the virus.
Releasing a small dose of nitric oxide, a natural nanomolecule with anti-microbial properties including against SARS-CoV-2, Enovid provides a physical and chemical barrier in the nose.
In June 2021, SaNOtize announced it had received approval from Health Canada to proceed with enrolment of volunteers in Phase III trials, and submitted an application for a New Drug Submission under Health Canada’s Interim Order.
NONS is the only novel therapeutic treatment so far proven to reduce viral load in humans that is not a monoclonal antibody treatment. Monoclonal antibodies are highly specific, expensive and must be administered intravenously in a clinical setting.
“I expect this to be a major advance in the global battle against the devastating human impacts of the COVID-19 pandemic,” said Dr. Stephen Winchester, Consultant Medical Virologist and Chief Investigator of this NHS Clinical Trial. “This simple portable nasal spray could be highly effective in the treatment of COVID-19 and reducing onward transmission. Our trial included patients with a variant of concern and high viral loads yet still demonstrated significant reductions in the levels of SARS-CoV-2, which could be critical in supporting vaccines, preventing future outbreaks and safely reopening economies. Simply stated, I think this could be revolutionary.”
The SaNOtize treatment is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs. It is based on nitric oxide (NO), a natural nanomolecule produced by the human body with proven anti-microbial properties shown to have a direct effect on SARS-CoV-2, the virus that causes COVID-19. The pharmacology, toxicity, and safety data for NO use in humans has been well-established for decades. The NO molecule released from NONS is identical to the one delivered in its gaseous form to treat persistent pulmonary hypertension, or Blue Baby Syndrome, in newborn babies.
SaNOtize Seeking Emergency Use Authorization in UK and Canada
SaNOtize is applying to regulatory authorities in the UK and Canada for Emergency Use authorization. Swift approval and ramp-up of manufacturing could facilitate an almost immediate safe return to work, school and society, and spur an economic recovery that is months – if not years – ahead of full global vaccination.
Wide-scale equitable global availability of NONS could form a bridge during the global production and distribution of vaccines to help keep people safe and healthy. The ease of NONS manufacture, storage and use makes NONS a treatment candidate that could soon be widely available at low-cost for long-term care facilities, healthcare and frontline workers, and the general population.
In addition to providing antiviral treatment in the early stages of infection and for those who have yet to be vaccinated, NONS has also demonstrated that it could also reduce infectivity – the frequency of transmission from an infected person to a non-infected person.
The results of the UK trial corroborate the information gathered from SaNOtize’s earlier Phase 2 trials in Canada and independent lab tests at Utah State University’s Antiviral Research Institute.
“Now that NONS has been demonstrated to be safe and effective in clinical trials, we must move with urgency to get it into the hands of the public where it can help bring an end to the pandemic, accelerate a return to normality, and prevent future outbreaks of COVID-19 and its variants,” said Dr. Gilly Regev, CEO and co-founder of SaNOtize. “The human toll of this disease cannot be expressed simply in numbers, and each day compounds the frustration, fear and loss suffered by millions around the world. Combined with the roll-out of vaccines, NONS can help get the world back on its feet.”
Positive Phase 3 Study Results
In February 2022, the company reported a Phase 3 trial achieve its primary endpoint while demonstrating a reduction in SARS-CoV-2 log viral load in COVID-19 patients by over 94% within 24 hours of treatment. Within 48 hours the viral load was wiped out by 99%.
Moreover, a greater proportion of people in the high risk group, numbering 218, achieved a combination of clinical and virological cure, based on the WHO Progression Scale. They report a stunning medical time to virological cure at 4 days in the treatment group and eight days in the placebo group (p<0.05). Moreover, Glenmark Pharmaceuticals received manufacturing and marketing approval for the Nitric Oxide Nasal Spray (NONS) as part of an accelerated approval process.
Co-Founder and CEO Gilly Regev shared with TrialSite’s Founder Daniel O’Connor, “SaNOtize is excited to have Glenmark as our partner for manufacturing and distribution in India. We share the vision for this product and hoping it will become the first line of treatment and defence against respiratory viral infections.”
In late August 2022, it was also reported that Enovid’s manufacturer raised $24M to fund an ongoing phase 3 prevention trial. Sanotize Nasal Spray Where to Buy | Enovid Nasal Spray Amazon
Canadian biotech SaNOtize’s nitric oxide nasal spray Enovid became available in pharmacies in Israel in July 2021 as a treatment for Covid-19. You can purchase it online on Amazon.com.
Glenmark Pharmaceuticals has signed a partnership with Canadian company SaNOtize Research & Development Corp., to manufacture, market and distribute Nitric Oxide Nasal Spray (NONS) for COVID-19 treatment in India and Asian markets including Malaysia, Singapore, Hong Kong, Taiwan, Brunei, Nepal, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam.
Canadian biotech SaNOtize’s nitric oxide nasal spray Enovid became available in pharmacies in Israel in July 2021 as a treatment for Covid-19.
The spray received emergency use authorisation in Israel in early July 2021 after Phase II trials showed it reduces SARS-CoV-2 viral load, and therefore decrease a person’s transmission of the virus.
Releasing a small dose of nitric oxide, a natural nanomolecule with anti-microbial properties including against SARS-CoV-2, Enovid provides a physical and chemical barrier in the nose.
In June 2021, SaNOtize announced it had received approval from Health Canada to proceed with enrolment of volunteers in Phase III trials, and submitted an application for a New Drug Submission under Health Canada’s Interim Order.
NONS is the only novel therapeutic treatment so far proven to reduce viral load in humans that is not a monoclonal antibody treatment. Monoclonal antibodies are highly specific, expensive and must be administered intravenously in a clinical setting.
“I expect this to be a major advance in the global battle against the devastating human impacts of the COVID-19 pandemic,” said Dr. Stephen Winchester, Consultant Medical Virologist and Chief Investigator of this NHS Clinical Trial.
“This simple portable nasal spray could be highly effective in the treatment of COVID-19 and reducing onward transmission. Our trial included patients with a variant of concern and high viral loads yet still demonstrated significant reductions in the levels of SARS-CoV-2, which could be critical in supporting vaccines, preventing future outbreaks and safely reopening economies. Simply stated, I think this could be revolutionary.”
The SaNOtize treatment is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs. It is based on nitric oxide (NO), a natural nanomolecule produced by the human body with proven anti-microbial properties shown to have a direct effect on SARS-CoV-2, the virus that causes COVID-19. The pharmacology, toxicity, and safety data for NO use in humans has been well-established for decades. The NO molecule released from NONS is identical to the one delivered in its gaseous form to treat persistent pulmonary hypertension, or Blue Baby Syndrome, in newborn babies.
The SaNOtize treatment is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs. It is based on nitric oxide (NO), a natural nanomolecule produced by the human body with proven anti-microbial properties shown to have a direct effect on SARS-CoV-2, the virus that causes COVID-19. The pharmacology, toxicity, and safety data for NO use in humans has been well-established for decades. The NO molecule released from NONS is identical to the one delivered in its gaseous form to treat persistent pulmonary hypertension, or Blue Baby Syndrome, in newborn babies.
SaNOtize Seeking Emergency Use Authorization in UK and Canada
SaNOtize is applying to regulatory authorities in the UK and Canada for Emergency Use authorization. Swift approval and ramp-up of manufacturing could facilitate an almost immediate safe return to work, school and society, and spur an economic recovery that is months – if not years – ahead of full global vaccination.
Wide-scale equitable global availability of NONS could form a bridge during the global production and distribution of vaccines to help keep people safe and healthy. The ease of NONS manufacture, storage and use makes NONS a treatment candidate that could soon be widely available at low-cost for long-term care facilities, healthcare and frontline workers, and the general population.
In addition to providing antiviral treatment in the early stages of infection and for those who have yet to be vaccinated, NONS has also demonstrated that it could also reduce infectivity – the frequency of transmission from an infected person to a non-infected person.
The results of the UK trial corroborate the information gathered from SaNOtize’s earlier Phase 2 trials in Canada and independent lab tests at Utah State University’s Antiviral Research Institute.
“Now that NONS has been demonstrated to be safe and effective in clinical trials, we must move with urgency to get it into the hands of the public where it can help bring an end to the pandemic, accelerate a return to normality, and prevent future outbreaks of COVID-19 and its variants,” said Dr. Gilly Regev, CEO and co-founder of SaNOtize. “The human toll of this disease cannot be expressed simply in numbers, and each day compounds the frustration, fear and loss suffered by millions around the world. Combined with the roll-out of vaccines, NONS can help get the world back on its feet.”
Positive Phase 3 Study Results
In February 2022, the company reported a Phase 3 trial achieve its primary endpoint while demonstrating a reduction in SARS-CoV-2 log viral load in COVID-19 patients by over 94% within 24 hours of treatment. Within 48 hours the viral load was wiped out by 99%.
Moreover, a greater proportion of people in the high risk group, numbering 218, achieved a combination of clinical and virological cure, based on the WHO Progression Scale. They report a stunning medical time to virological cure at 4 days in the treatment group and eight days in the placebo group (p<0.05). Moreover, Glenmark Pharmaceuticals received manufacturing and marketing approval for the Nitric Oxide Nasal Spray (NONS) as part of an accelerated approval process.
Sanotize Nasal Spray Where to Buy | Enovid Nasal Spray Amazon
Canadian biotech SaNOtize’s nitric oxide nasal spray Enovid became available in pharmacies in Israel in July 2021 as a treatment for Covid-19. You can purchase it online on Amazon.com.
Glenmark Pharmaceuticals has signed a partnership with Canadian company SaNOtize Research & Development Corp., to manufacture, market and distribute Nitric Oxide Nasal Spray (NONS) for COVID-19 treatment in India and Asian markets including Malaysia, Singapore, Hong Kong, Taiwan, Brunei, Nepal, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam.
5. Iota-Carrageenan Nasal Spray for COVID-19
Iota-carrageenan nasal spray is also being studied as a way to prevent COVID-19. Iota-carrageenan is a sugar that comes from algae.
Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that Carragelose inactivates the new, rapidly spreading variants and SARS-CoV-2 wildtype with similar efficacy in vitro. The Company tested the three variants that currently mostly drive the COVID-19 pandemic, namely the so-called British or B.1.1.7, the South-African or B.1.351, and the Brazilian or P1 variant.[*] The data demonstrate that also with increasing prevalence of virus variants, the marketed OTC Carragelose-based lozenges, nasal and throat sprays will continue to effectively contribute to combatting the COVID-19 pandemic.
“The COVID-19 pandemic continues to be a major health, social, and economic burden, and we now see variants of SARS-CoV-2 taking over the dynamics of the pandemic. We are very confident in these results that show Carragelose inactivates SARS-CoV-2, independent of the mutations we tested,” said Dr. Eva Prieschl-Grassauer, Chief Scientific Officer at Marinomed. “Given the broad antiviral efficacy and the physical mode of action, we were convinced that SARS‑CoV‑2 variants are unlikely to evade the antiviral efficacy of Carragelose. With these new results we confirmed the hypothesis that our Carragelose-based products continue to be effective also against the mutations of concern currently emerging strongly. We believe that this will hold true for any future variants.”
In recent in vitro tests, Marinomed included four lentiviruses differently pseudotyped with the spike protein of wild-type SARS-CoV-2 or one of the three variants B.1.1.7, B1.351 and P1, respectively. Carragelose was able to inactivate all four virus forms at concentrations below 5 µg/ml. This is clinically relevant for the use of Carragelose-containing products: The marketed nasal sprays have a Carragelose concentration of 1.2 mg / ml, a more than 200-fold higher dose as shown to be effective in vitro. The non-sulfated polymers HPMC and CMC were ineffective even at the highest concentrations tested.
In addition, two of the three SARS-CoV-2 variants (B1.1.7 and B1.351) were independently tested in Vero cell tissue culture in cooperation with the virological institute of the University Hospital Erlangen, Germany. Carragelose showed similar effectiveness against the SARS-CoV-2 wild type and the tested variants.
Marinomed’s lentivirus data show the ability of Carragelose to prevent the virus from attaching to the host cell. The infectious virus particles used in the cooperation with the virological institute of the University Hospital Erlangen mimic the effect of an actual infection, where the virus replicates in the host cells and then reinfects further cells, thereby spreading the infection in the body. Both are established and scientifically widely accepted models. Taken together, the data show how Carragelose can effectively inhibit SARS-CoV-2 variants in tissue culture. The cooperation partners plan to publish the data in a peer reviewed journal.
So far, one study of about 400 healthcare workers suggested that iota-carrageenan may potentially lower the risk of getting COVID-19 by up to 80%. Another study is looking to analyze iota-carrageenan’s ability to prevent COVID-19, but it's still recruiting participants. This study is expected to wrap up by February 2023.About Carragelose®:
Carragelose® is a sulfated polymer from red seaweed and is a unique, broadly active anti-viral compound. It is known as a gentle yet effective and safe prevention and treatment against respiratory infections. Several clinical and preclinical studies have shown that Carragelose® forms a layer on the mucosa wrapping entering viruses, thereby inactivating them, and preventing them from infecting cells. Increasing clinical evidence indicates that Carragelose® can also inactivate SARS-CoV-2.[1],[2]
Marinomed is holder of the IP rights and has licensed Carragelose® for marketing in Europe, parts of Asia, Canada, and Australia. For a full list of Marinomed’s portfolio of Carragelose® containing nasal sprays and oral products, please visit https://www.carragelose.com/en/portfolio/launched-products, for a list of scientific publications on Carragelose®, https://www.carragelose.com/en/publications.
References:
Iota-carrageenan nasal spray is also being studied as a way to prevent COVID-19. Iota-carrageenan is a sugar that comes from algae.
Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that Carragelose inactivates the new, rapidly spreading variants and SARS-CoV-2 wildtype with similar efficacy in vitro. The Company tested the three variants that currently mostly drive the COVID-19 pandemic, namely the so-called British or B.1.1.7, the South-African or B.1.351, and the Brazilian or P1 variant.[*] The data demonstrate that also with increasing prevalence of virus variants, the marketed OTC Carragelose-based lozenges, nasal and throat sprays will continue to effectively contribute to combatting the COVID-19 pandemic.
In recent in vitro tests, Marinomed included four lentiviruses differently pseudotyped with the spike protein of wild-type SARS-CoV-2 or one of the three variants B.1.1.7, B1.351 and P1, respectively. Carragelose was able to inactivate all four virus forms at concentrations below 5 µg/ml. This is clinically relevant for the use of Carragelose-containing products: The marketed nasal sprays have a Carragelose concentration of 1.2 mg / ml, a more than 200-fold higher dose as shown to be effective in vitro. The non-sulfated polymers HPMC and CMC were ineffective even at the highest concentrations tested.
In addition, two of the three SARS-CoV-2 variants (B1.1.7 and B1.351) were independently tested in Vero cell tissue culture in cooperation with the virological institute of the University Hospital Erlangen, Germany. Carragelose showed similar effectiveness against the SARS-CoV-2 wild type and the tested variants.
Marinomed’s lentivirus data show the ability of Carragelose to prevent the virus from attaching to the host cell. The infectious virus particles used in the cooperation with the virological institute of the University Hospital Erlangen mimic the effect of an actual infection, where the virus replicates in the host cells and then reinfects further cells, thereby spreading the infection in the body. Both are established and scientifically widely accepted models. Taken together, the data show how Carragelose can effectively inhibit SARS-CoV-2 variants in tissue culture. The cooperation partners plan to publish the data in a peer reviewed journal.
So far, one study of about 400 healthcare workers suggested that iota-carrageenan may potentially lower the risk of getting COVID-19 by up to 80%. Another study is looking to analyze iota-carrageenan’s ability to prevent COVID-19, but it's still recruiting participants. This study is expected to wrap up by February 2023.
About Carragelose®:
Carragelose® is a sulfated polymer from red seaweed and is a unique, broadly active anti-viral compound. It is known as a gentle yet effective and safe prevention and treatment against respiratory infections. Several clinical and preclinical studies have shown that Carragelose® forms a layer on the mucosa wrapping entering viruses, thereby inactivating them, and preventing them from infecting cells. Increasing clinical evidence indicates that Carragelose® can also inactivate SARS-CoV-2.[1],[2]
Marinomed is holder of the IP rights and has licensed Carragelose® for marketing in Europe, parts of Asia, Canada, and Australia. For a full list of Marinomed’s portfolio of Carragelose® containing nasal sprays and oral products, please visit https://www.carragelose.com/en/portfolio/launched-products, for a list of scientific publications on Carragelose®, https://www.carragelose.com/en/publications.
References:
6. Nasal spray vaccines
A number of COVID-19 nasal spray vaccines are also being researched and developed. It’s thought that they could help build up protective antibodies in your nose that fight SARS-CoV-2.
Several COVID-19 nasal spray vaccines are being researched in studies — 13 intranasal and 2 inhaled to be exact. They aim to build up protective antibodies in your nose that fight SARS-CoV-2, the virus that causes COVID-19. A few are authorized in Asia, but none are available in the U.S. yet.
China has become the first country to approve an inhaled Covid vaccine. Made by CanSino (“CanSinoBIO”) (SSE: 688185, HKEX: 06185), Convidecia Air has similar ingredients to its injected vaccine, using a harmless adenovirus as a carrier for the genetic code that teaches the body how to fight Covid.
Inhaled as a fine mist, Convidecia Air can provide good protection after just one breath, the company says.
Other researchers, including teams in the UK and the US, have been investigating nasal spray vaccines.
Scientists say these may give added immunity in the lining of the nose and upper airways, where Covid typically enters the body.
The National Medical Products Administration of China granted CanSino approval for its inhaled vaccine to be used as a booster dose.
It can top up protection in those who have previously had a jab, trials suggest.
A number of COVID-19 nasal spray vaccines are also being researched and developed. It’s thought that they could help build up protective antibodies in your nose that fight SARS-CoV-2.
Several COVID-19 nasal spray vaccines are being researched in studies — 13 intranasal and 2 inhaled to be exact. They aim to build up protective antibodies in your nose that fight SARS-CoV-2, the virus that causes COVID-19. A few are authorized in Asia, but none are available in the U.S. yet.
China has become the first country to approve an inhaled Covid vaccine. Made by CanSino (“CanSinoBIO”) (SSE: 688185, HKEX: 06185), Convidecia Air has similar ingredients to its injected vaccine, using a harmless adenovirus as a carrier for the genetic code that teaches the body how to fight Covid.
Inhaled as a fine mist, Convidecia Air can provide good protection after just one breath, the company says.
Other researchers, including teams in the UK and the US, have been investigating nasal spray vaccines.
Scientists say these may give added immunity in the lining of the nose and upper airways, where Covid typically enters the body.
The National Medical Products Administration of China granted CanSino approval for its inhaled vaccine to be used as a booster dose.
It can top up protection in those who have previously had a jab, trials suggest.
China has become the first country to approve an inhaled Covid vaccine. Made by CanSino (“CanSinoBIO”) (SSE: 688185, HKEX: 06185), Convidecia Air has similar ingredients to its injected vaccine, using a harmless adenovirus as a carrier for the genetic code that teaches the body how to fight Covid.
Inhaled as a fine mist, Convidecia Air can provide good protection after just one breath, the company says.
Other researchers, including teams in the UK and the US, have been investigating nasal spray vaccines.
Scientists say these may give added immunity in the lining of the nose and upper airways, where Covid typically enters the body.
The National Medical Products Administration of China granted CanSino approval for its inhaled vaccine to be used as a booster dose.
7. Steroid nasal sprays
Corticosteroid (steroid) nasal sprays are available widely in the U.S., and they’re often used for treating conditions like allergies and nasal polyps. But some researchers are exploring their potential as a treatment option for COVID-19. It’s thought that these sprays can help control inflammation while also stopping the coronavirus from entering your respiratory system.
In one Cleveland Clinic study, registry data from over 70,000 people with mild-to-moderate COVID-19 was collected. Results suggested that corticosteroid nasal sprays may help prevent hospitalizations, ICU admissions, or death from COVID-19. But to see if they’re truly safe and effective for COVID-19, clinical trials would need to be performed.
Related: Inhaled Budesonide and COVID-19
Corticosteroid (steroid) nasal sprays are available widely in the U.S., and they’re often used for treating conditions like allergies and nasal polyps. But some researchers are exploring their potential as a treatment option for COVID-19. It’s thought that these sprays can help control inflammation while also stopping the coronavirus from entering your respiratory system.
In one Cleveland Clinic study, registry data from over 70,000 people with mild-to-moderate COVID-19 was collected. Results suggested that corticosteroid nasal sprays may help prevent hospitalizations, ICU admissions, or death from COVID-19. But to see if they’re truly safe and effective for COVID-19, clinical trials would need to be performed.
Related: Inhaled Budesonide and COVID-19
In one Cleveland Clinic study, registry data from over 70,000 people with mild-to-moderate COVID-19 was collected. Results suggested that corticosteroid nasal sprays may help prevent hospitalizations, ICU admissions, or death from COVID-19. But to see if they’re truly safe and effective for COVID-19, clinical trials would need to be performed.
Related: Inhaled Budesonide and COVID-19
What medications can I take to treat or prevent COVID-19?
Nasal sprays aside, many medications are already authorized to treat and prevent COVID-19. Your healthcare provider can tell you if you’re eligible to access any of these treatments.
Nasal sprays aside, many medications are already authorized to treat and prevent COVID-19. Your healthcare provider can tell you if you’re eligible to access any of these treatments.
Medications that can treat COVID-19 if you aren’t in the hospital
If you’ve tested positive for COVID-19 and aren’t in the hospital, your healthcare provider may prescribe a medication to help lower your risk of severe illness. Listed in preferential order (NIH), these include:
- Paxlovid (nirmatrelvir and ritonavir), an oral tablet
- Veklury (remdesivir), an intravenous (IV) infusion
- Bebtelovimab, another IV infusion
- Lagevrio (molniupiravir), an oral capsule
- Paxlovid (nirmatrelvir and ritonavir), an oral tablet
- Veklury (remdesivir), an intravenous (IV) infusion
- Bebtelovimab, another IV infusion
- Lagevrio (molniupiravir), an oral capsule
NB: Treatment of COVID-19 is a highly dynamic topic. Please refer to the
latest FLCCC protocol.
Related:
- Antiviral Nasal Spray Shows Promise Fighting COVID-19 (Results were published on March 28, 2022, in Nature)
Please feel free to send us corrections, updates or comments
below.
.png)
Comments
Post a Comment